We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-0.47%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.52M
AUM Growth
-$6.16B
Cap. Flow
-$249M
Cap. Flow %
-4,517.93%
Top 10 Hldgs %
32.16%
Holding
158
New
15
Increased
26
Reduced
36
Closed
15

Top Buys

Rank Stock Value
1
PGNY icon
Progyny
PGNY
+$22.4M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$19.5M
3
TVTX icon
Travere Therapeutics
TVTX
+$19.4M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$17.1M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$17.1M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$76.7M
2
PFE icon
Pfizer
PFE
+$59.2M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$50.3M
4
NSTG
NanoString Technologies, Inc.
NSTG
+$40.2M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$34.3M

Sector Composition

Rank Sector Weight
1 Healthcare 97.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
26
argenx
ARGX
$55B
$73.5K 1.33%
194,000
+24,200
+14% +$7.79M
MRTX
27
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$73.2K 1.33%
1,090,400
-540,100
-33% -$34.3M
GBT
28
DELISTED
Global Blood Therapeutics, Inc.
GBT
$65.3K 1.18%
2,044,000
+467,400
+30% +$13.7M
TMO icon
29
Thermo Fisher Scientific
TMO
$215B
$61.6K 1.12%
113,400
-7,200
-6% -$3.96M
CRNX icon
30
Crinetics Pharmaceuticals
CRNX
$8.87B
$59.6K 1.08%
3,196,876
– –
NTRA icon
31
Natera
NTRA
$35.9B
$58.9K 1.07%
1,661,353
+65,968
+4% +$2.44M
CMPX icon
32
Compass Therapeutics
CMPX
$360M
$58.2K 1.05%
21,960,850
+317,875
+1% +$690K
EVH icon
33
Evolent Health
EVH
$405M
$54.6K 0.99%
1,778,000
+378,000
+27% +$11M
PRLD icon
34
Prelude Therapeutics
PRLD
$366M
$52.4K 0.95%
10,039,691
– –
KNTE
35
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$51K 0.92%
4,043,629
– –
RPTX
36
DELISTED
Repare Therapeutics
RPTX
$46.5K 0.84%
3,322,488
– –
KROS icon
37
Keros Therapeutics
KROS
$197M
$46.4K 0.84%
1,679,417
– –
SNDX icon
38
Syndax Pharmaceuticals
SNDX
$1.7B
$44.7K 0.81%
2,323,300
+165,000
+8% +$2.75M
ABCL icon
39
AbCellera Biologics
ABCL
$1.68B
$44.5K 0.81%
4,180,768
– –
SIBN icon
40
SI-BONE Inc
SIBN
$800M
$44.5K 0.81%
3,368,000
+228,753
+7% +$3.81M
GRCL
41
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$43.4K 0.79%
7,884,870
– –
GH icon
42
Guardant Health
GH
$18.8B
$41.7K 0.76%
1,033,400
-292,000
-22% -$14.5M
MRSN
43
DELISTED
Mersana Therapeutics
MRSN
$41.6K 0.75%
360,457
+168,901
+88% +$15.9M
XENE icon
44
Xenon Pharmaceuticals
XENE
$6.25B
$40.4K 0.73%
1,329,200
+643,200
+94% +$19.5M
XTNT icon
45
Xtant Medical Holdings
XTNT
$57.7M
$37.9K 0.69%
72,943,918
– –
SPRY icon
46
ARS Pharmaceuticals
SPRY
$538M
$37.1K 0.67%
8,740,887
– –
VECT
47
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$35K 0.63%
6,473,561
+1,142,857
+21% +$6.15M
ALPN
48
DELISTED
Alpine Immune Sciences Inc
ALPN
$34.7K 0.63%
4,081,592
– –
JANX icon
49
Janux Therapeutics
JANX
$901M
$34.6K 0.63%
2,836,386
– –
THC icon
50
Tenet Healthcare
THC
$22.3B
$34.5K 0.63%
656,300
+28,000
+4% +$1.95M
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q2 2022 Portfolio in Review

As of Q2 2022, OrbiMed held 158 positions worth $5.52M, down 100% from $6.17B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

OrbiMed withdrew a net $249M in Q2 2022, closing 15 positions and reducing 36 holdings. Its most notable exit was DexCom, an estimated $76.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier.

Against the trend, OrbiMed opened a new position in Progyny worth $18.2K.

  • OrbiMed's largest Q2 2022 buy was Progyny: 625,000 shares worth $18.2K.
  • OrbiMed added most to Xenon Pharmaceuticals in Q2 2022, an estimated $19.5M increase.
  • OrbiMed's biggest Q2 2022 reduction was Pfizer, cutting an estimated $59.2M.
  • OrbiMed fully exited DexCom in Q2 2022, selling an estimated $76.7M.
  • OrbiMed's ten largest holdings make up 32% of its $5.52M portfolio in Q2 2022.
  • OrbiMed opened 15 new positions and closed 15 in Q2 2022.
  • OrbiMed's portfolio value fell 100% quarter-over-quarter to $5.52M.

Based on OrbiMed's 13F filing for Q2 2022, filed 15 Aug 2022.